Abstracts Archive - Page 2174 of 2607 - ACR Meeting Abstracts

Abstract Number: 891 • 2014 ACR/ARHP Annual Meeting
Randomized Clinical Trial of Group Vs. Individual Physical Therapy for Knee Osteoarthritis
Kelli D. Allen¹, Dennis Bongiorni², Hayden B. Bosworth³, Cynthia Coffman³, Santanu Datta⁴, David Edelman³, Jennifer H. Lindquist⁵, Eugene Oddone³ and Helen Hoenig⁶, ¹Health Services Research, Durham VA Medical Center and University of North Carolina at Chapel Hill, Durham, NC, ²Durham VA Medical Center, Durham, NC, ³Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC, ⁴Health Services Reserach, Durham VA Medical Center and Duke University Medical Center, Durham, NC, ⁵Health Services Research, Durham VA Medical Center, Durham, NC, ⁶Durham VA Medical Center and Duke University Medical Center, Durham, NC
Background/Purpose: Physical therapy (PT) is a key component of treatment for knee osteoarthritis (OA). There is a high demand for PT services in many healthcare…
Abstract Number: 890 • 2014 ACR/ARHP Annual Meeting
Test of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Item Profile in a Large Cohort of Rheumatic Disease Patients
Patricia P. Katz¹, Sofia Pedro² and Kaleb Michaud³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²1035 N Emporia Ste 288, National Data Bank, Wichita, KS, ³University of Nebraska Medical Center and National Data Bank, Omaha, NE
Background/Purpose: Patient-reported outcomes are routinely used in rheumatology research and clinical care. Yet, often outcomes cannot be compared across studies or diseases because a variety…
Abstract Number: 889 • 2014 ACR/ARHP Annual Meeting
Exercise, Manual Therapy, and Use of Booster Sessions in Physical Therapy for Knee OA: A Multi-Center Randomized Clinical Trial
G Kelley Fitzgerald¹, Julie Fritz², John Childs³, Gerard P. Brennan⁴, Douglas P. Landsittel⁵, Brett Neilson⁶, Alexandra Gil¹ and J. Haxby Abbott⁷, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Physical Therapy, University of Utah, Salt Lake City, UT, ³US Army-Baylor University, Schertz, TX, ⁴Rehabilitation Services, Intermountain Healthcare, Murray, UT, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Henry M. Jackson Foundation, Bethesda, MD, ⁷Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand
Background/Purpose: There is need to improve the magnitude and duration of treatment effects of exercise therapy (ET) for patients with knee osteoarthritis (KOA). There is…
Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Miriam G. Cisternas¹, Louise Murphy², David J. Pasta³, Edward H. Yelin⁴ and Charles Helmick⁵, ¹MGC Data Services, Carlsbad, CA, ²Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA, ³DMA Corporation, Palo Alto, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…
Abstract Number: 887 • 2014 ACR/ARHP Annual Meeting
Serological and Clinical Characteristics of a Large Collection of Incomplete Lupus Erythematosus Patients
Teresa Aberle¹, Virginia C. Roberts¹, Julie M. Robertson¹, Joel M. Guthridge¹, Kathy L. Sivils², Astrid Rasmussen², David R. Karp³ and Judith James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Incomplete lupus (ILE) is defined as a condition in which patients present with signs of systemic autoimmunity and clinical manifestations compatible with systemic lupus…
Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Nancy A. Baker¹, Heather Eng², Juan (June) Feng², Jason Lyons², Yong Gil Hwang³, Kimberly P. Liang⁴ and Larry W. Moreland⁵, ¹Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…
Abstract Number: 885 • 2014 ACR/ARHP Annual Meeting
A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
Eric L. Matteson¹, Bhaskar Dasgupta², Wolfgang A. Schmidt³, Carlo Salvarani⁴, Nagui Gendi⁵, Mauro Galeazzi⁶, Sylvie Stitah⁷, Yue Li⁸, Marie-Anne Valentin⁹, Bolan Linghu¹⁰ and Stephen J. Oliver⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Southend University Hospital, Essex, United Kingdom, ³Rheumatology, Immanuel Krankenhaus, Berlin, Germany, ⁴Rheumatology Unit, Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, ⁵Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, ⁶Sezione di Reumatologia, Università di Siena, Siena, Italy, ⁷Translational Medicine, Novartis Pharma AG, Basel, Switzerland, ⁸IIS, Novartis Pharma AG, Basel, Switzerland, ⁹Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ¹⁰Translational Medicine, Novartis Pharma AG, Cambridge, MA
Background/Purpose To assess the effects of a single dose of secukinumab or canakinumab in patients with new onset, untreated polymyalgia rheumatica (PMR). Methods In this…
Abstract Number: 884 • 2014 ACR/ARHP Annual Meeting
Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis
Lorraine O'Neill¹, Jennifer McCormick², Wei Gao², Conor Murphy³, Geraldine M. McCarthy⁴, Douglas J. Veale⁵, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁵Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Interleukin 6 (IL 6) is postulated to play a role in the pathogenesis of Giant Cell Arteritis. Several studies have demonstrated increased circulating IL…
Abstract Number: 883 • 2014 ACR/ARHP Annual Meeting
Accuracy of High Resolution MRI of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Study
Maxime Rhéaume¹, Ryan Rebello², Christian Pagnoux³, Simon Carette³, Marie Clements-Baker⁴, Violette Cohen-Hallaleh², David Doucette-Preville², B. Stanley Jackson⁵, Sam Salama⁶, George Ioannidis⁷ and Nader A. Khalidi¹, ¹Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ²Department of Radiology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Queens University, Kingston, ON, Canada, ⁵Department of Surgery, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁶Department of Pathology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁷St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Temporal artery biopsy (TAB) remains the gold standard for the diagnosis of giant cell arteritis (GCA). It is invasive and its sensitivity is limited…
Abstract Number: 881 • 2014 ACR/ARHP Annual Meeting
DNA Methylation Analysis of the Temporal Artery Microenvironment Reveals a Robust T Cell Signature and Suggests a Role for TNF-α in Giant Cell Arteritis
Patrick S. Coit¹, Lindsey B. De Lott², Bin Nan³, Victor M. Elner⁴ and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics, University of Michigan, Ann Arbor, MI, ⁴Department of Ophthalmology and Visual Sciences & Department of Pathology, University of Michigan, Ann Arbor, MI
Background/Purpose: Giant cell arteritis (GCA) is a systemic large vessel vasculitis of unknown etiology. A hallmark of GCA is the presence of granulomatous inflammation of…
Abstract Number: 880 • 2014 ACR/ARHP Annual Meeting
An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis
Francisco David Carmona¹, Sarah Mackie², Jose Ezequiel Martin¹, John Taylor², Augusto Vaglio³, Lara Bossini-Castillo¹, Santos Castañeda⁴, Maria C. Cid⁵, José Hernández-Rodríguez⁶, Roser Solans⁷, Ricardo Blanco⁸, Lorenzo Beretta⁹, Claudio Lunardi¹⁰, Marco A. Cimmino¹¹, Cisca Wijmenga¹², Torsten Witte¹³, Julia Holle¹⁴, Frank Moosig¹⁴, Verena Schönau¹⁵, Andre Franke¹⁶, Øyvind Palm¹⁷, Andreas P. Diamantopoulos¹⁸, Benedicte A. Lie¹⁹, Simon Carette²⁰, David Cuthbertson²¹, Gary S. Hoffman²², Nader A. Khalidi²³, Curry L. Koening²⁴, Carol A. Langford²⁵, Carol McAlear²⁶, Larry Moreland²⁷, Paul A. Monach²⁸, Christian Pagnoux²⁰, Philip Seo²⁹, Antoine G. Sreih³⁰, Kenneth J. Warrington³¹, Steven R. Ytterberg³¹, Colin T. Pease³², Andrew Gough³³, Michael Green³⁴, Lesley Hordon³⁵, Stephen Jarrett³⁶, Richard Watts³⁷, Sarah Levy³⁸, Yusuf Patel³⁹, Sanjeet Kamath⁴⁰, Bhaskar Dasgupta⁴¹, Paul IW. de Bakker⁴², Bobby P.C. Koeleman⁴², Jennifer H. Barrett², Carlo Salvarani⁴³, Peter A. Merkel⁴⁴, Miguel A. Gonzalez-Gay⁸, Ann W. Morgan² and Javier Martin¹, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ³Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁴Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁵Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036- Barcelona, Spain, ⁶Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁷Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, ⁹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁰Department of Medicine, Università degli Studi di Verona, Verona, Italy, ¹¹Department of Internal Medicine, Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy, ¹²Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ¹³Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ¹⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ¹⁵Department of Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁶Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁷Department of Rheumatology, Oslo University Hospital and University of Oslo, Oslo, Norway, ¹⁸Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁹Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ²⁰Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²¹Department of Biostatistics, University of South Florida, Tampa, FL, ²²Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²³Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ²⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ²⁵Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ²⁶Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ²⁷Rheumatology & Clinical Immunology, Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ²⁸Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ²⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ³⁰Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ³¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ³²Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³³Department of Rheumatology, Harrogate and District Foundation Trust, Harrogate, United Kingdom, ³⁴Department of Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ³⁵Department of Rheumatology, Mid Yorkshire Hospitals NHS Trust, Dewsbury, United Kingdom, ³⁶Department of Rheumatology, Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom, ³⁷Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ³⁸Department of Rheumatology, Croydon Health Service NHS Trust, Croydon, United Kingdom, ³⁹Department of Rheumatology, Hull and East Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom, ⁴⁰Department of Rheumatology, Staffordshire and Stoke-on-Trent Partnership NHS Trust, Staffordshire, United Kingdom, ⁴¹Department of Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴²Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴³Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ⁴⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a chronic autoimmune vasculitis with an important genetic component. We aimed to identify relevant risk loci for GCA predisposition…
Abstract Number: 899 • 2014 ACR/ARHP Annual Meeting
Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis
Laura Plantinga¹, Cristina M. Drenkard², Rachel Patzer³, William McClellan¹, Stephen Pastan⁴ and S. Sam Lim⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Medicine, Div Rheumatology, Emory University, Atlanta, GA, ³Department of Surgery, Emory University, Atlanta, GA, ⁴Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Prior data suggest sociodemographic and regional variability in various indicators of quality of end-stage renal disease (ESRD) care, both overall and in the SLE…
Abstract Number: 898 • 2014 ACR/ARHP Annual Meeting
Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting
J An¹, K Reynolds², E Alemao³, H Kawabata³, D H Solomon⁴, K P Liao⁵ and T C Cheetham², ¹Western University of Health Sciences, Pomona, CA, ²Kaiser Permanente Southern California, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Studies have suggested suboptimal care of traditional cardiovascular risk factors (CRF) in patients (pts) with RA as a reason for elevated CV risk compared…
Abstract Number: 882 • 2014 ACR/ARHP Annual Meeting
A Signature of microRNAs Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis
Stefania Croci¹, Alessandro Zerbini¹, Luigi Boiardi², Francesco Muratore², Alessandra Bisagni³, Giulia Pazzola², Luca Cimino⁴, Antonio Moramarco⁴, Davide Nicoli⁵, Enrico Farnetti⁶, Bruno Casali⁶, Alberto Cavazza³, Maria Parmeggiani⁷ and Carlo Salvarani², ¹Clinical Immunology, Allergology and Advanced Biotechnologies Unit,, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Laboratory of Molecular Biology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁶Laboratory of Molecular Biology,, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷Clinical Immunology, Allergology and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: MicroRNAs (miRNAs) are small, non-coding RNAs that suppress gene expression at post-transcriptional level. MiRNAs can regulate innate and adaptive immunity. Moreover, they have been…
Abstract Number: 878 • 2014 ACR/ARHP Annual Meeting
Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
D. James Haddon¹, Hannah Wand², Paul J. Utz¹, Robert F. Spiera³, Jessica K. Gordon³ and Lorinda Chung⁴, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose Tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have been studied for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc). In a previously reported single…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].